ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis and ImmunoGen will collaborate on drugs based on ImmunoGen’s Targeted Antibody Payload technology. Novartis will pay $45 million for rights to use the technology, which attaches antibodies to potent cancer-killing agents, on several targets. ImmunoGen can also get milestone payments plus compensation for research and manufacturing done for Novartis. Separately, Merck Serono and Ablynx have formed a second agreement to discover therapeutic uses for Nanobodies, antibody-derived proteins from Ablynx said to combine the advantages of conventional antibodies with key small-molecule properties. Ablynx will get a $14 million up-front payment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X